Thrombocytopenia is a condition in which a person have a low blood platelet count. Platelets (thrombocytes) are colorless blood cells that help blood clot. Platelets stop bleeding by clumping and forming plugs in blood vessel injuries. Thrombocytopenia is a common problem in patients with cancer. Chemotherapy-induced thrombocytopenia can be treated with the help of thrombopoietin receptor agonists, thrombopoietic agents, and others drugs. These drugs can be in the form of oral or injectable.
Chemotherapy-induced Thrombocytopenia Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID 19) pandemic and lockdowns in various countries across the globe have impacted the financial status of business across all sectors. The COVID 19 pandemic and lockdown across the world have impacted the financial situation of several business sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of drugs of chemotherapy-induced thrombocytopenia. Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 108.2 million cases and 2.3 million deaths due to coronavirus disease (COVID-19) were reported up till February 14, 2021 across the globe. Moreover, on December 14, 2020, the U.K. authorities reported a new variant SARS-CoV-2 VOC 202012/01, of COVID-19 to the World Health Organization due to which parts of the U.K. entered the third COVID-19 lockdown. Similarly, on December 18, 2020, the national authorities in South Africa reported another new variant of COVID-19 501Y.V2. However, on December 11, 2020, the Pfizer-BioNTech COVID-19 vaccine received the first emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) and later on January 22, 2021, the National Comprehensive Cancer Network (NCCN) provided recommendations for COVID-19 vaccination in cancer patients.
Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the chemotherapy-induced thrombocytopenia therapeutics market during the forecast period.
The global chemotherapy-induced thrombocytopenia therapeutics market is estimated to be valued at US$ 1,327.5 million in 2020 and is expected to exhibit a CAGR of 5.0% during the forecast period (2020-2027).
Figure 1. Drug Class Segment of Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2027
Increasing clinical trials of drugs for treatment of chemotherapy-induced thrombocytopenia therapeutics and approvals from regulatory bodies are expected to drive growth of global chemotherapy-induced thrombocytopenia therapeutics market
Major factors assisting the market growth during the forecast period include rising number of clinical trials of drugs such as thrombopoietin receptor agonists for treatment of chemotherapy-induced thrombocytopenia therapeutics by the key players in the market. For instance, in October 2020, Swedish Orphan Biovitrum AB announced topline results from its phase 3 study of avatrombopag, an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT).
Furthermore, market key players are focused on gaining approvals for launch of drug from regulatory bodies, which is expected to drive growth of the global chemotherapy-induced thrombocytopenia therapeutics market. For instance, in February 2021, the US Food and Drug Administration (FDA) approved trilaciclib (Cosela; G1 Therapeutics, Inc.), as a protectant to decrease the incidence of chemotherapy-induced myelosuppression in adults receiving a platinum- or etoposide-containing chemotherapy regimen or a topotecan-based intervention for the treatment of extensive-stage small cell lung cancer.
|Base Year:||2019||Market Size in 2020:||US$ 1,327.5 Mn|
|Historical Data for:||2017 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||5.0%||2027 Value Projection:||US$ 1,866.4 Mn|
Amgen, Inc., Novartis AG., Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
|Restraints & Challenges:||
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Restraints
Growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period, owing to lack of approved drugs or therapeutics for the treatment of chemotherapy-induced thrombocytopenia. For instance, currently, Oprelvekin-recombinant interleukin-11 (IL-11) is the only thrombopoietic agent approved by the U.S. Food and Drug Administration in 1998 for the treatment of chemotherapy-induced thrombocytopenia. It is indicated for adults with solid tumors and lymphomas associated with severe chemotherapy-induced thrombocytopenia.
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market- Major Region
Asia Pacific is the major region in global chemotherapy-induced thrombocytopenia therapeutics market, which is estimated to be valued at US$ 297.1 Mn in 2020 and is estimated to increase to US$ 430.5 Mn by 2027 at a CAGR of 5.4% during the forecast period. This is attributed to initiatives taken by various organizations in Asia Pacific to create awareness, educate people, and raise funds for the chronic disease such as heart disease, cancer and diabetes. For instance, the Ministry of Health and Family Welfare, Government of India runs the breast cancer awareness month campaign and educate people about breast cancer. This is expected to rise demand for chemotherapy-induced thrombocytopenia therapeutics in the near future.
Figure 2. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Competitive Landscape
Key players operating in the global chemotherapy-induced thrombocytopenia therapeutics market include Amgen, Inc., Novartis AG., Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
Thrombocytopenia is a condition in which blood platelets are low in person’s body. Thrombocytes are colourless blood cells that help blood clot. Thrombocytopenia is common in cancer patients. The occurrence of chemotherapy-induced thrombocytopenia varies from person to person depending on the treatment used. Each chemotherapy agent differs in how it causes thrombocytopenia. Mostly chemotherapy-induced thrombocytopenia are caused by the gemcitabine-and platinum-based regimens used in chemotherapy. Alkylating agents affect stem cells, cyclophosphamide affects later megakaryocyte progenitors, bortezomib prevents platelet release from megakaryocytes, and some treatments promote platelet apoptosis. Thrombocytopenia can also occur with any infection or adverse drug reaction associated with cancer treatment. Chemotherapy-induced therapy can be particularly harmful, as it can delay chemotherapy, decrease the dose of chemotherapy drugs, increase medical expenses, and can cause induced bleeding.
The increasing number of cancer cases is expected to surge the number of chemotherapy procedures, and this is expected to drive the Euopean chemotherapy-induced thrombocytopenia therapeutics market. For instance, according to the World health Organization (WHO), over 3.7 million new cancer cases and 1.9 million death occur each year, and cancer represents the second most important cause of death and morbidity in 2012 in Europe, on a global scale, cancer accounted for 8.2 million deaths Currently, there are no approved treatments available for (chemotherapy-induced thrombocytopenia) CIT in the European Union.
However, growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period, owing to discontinuation of clinical trials due to failure of chemotherapy-induced thrombocytopenia therapeutics. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients